



STUDY PROTOCOL

Rationale and design of the brain magnetic resonance imaging protocol for FutureMS: a longitudinal multi-centre study of newly diagnosed patients with relapsing-remitting multiple sclerosis in Scotland [version 1; peer review: 2 approved]

Rozanna Meijboom ^{1,2}, Stewart J. Wiseman^{1,2}, Elizabeth N. York ^{1,2}, Mark E. Bastin^{1,2}, Maria del C. Valdés Hernández^{1,2}, Michael J. Thrippleton^{1,2}, Daisy Mollison^{1,2}, Nicole White^{1,2}, Agniete Kampaite^{1,2}, Koy Ng Kee Kwong^{1,2}, David Rodriguez Gonzalez^{1,2}, Dominic Job^{1,2}, Christine Weaver³, Patrick K. A. Kearns ^{1,3}, Peter Connick^{1,3}, Siddharthan Chandran^{1,3}, Adam D. Waldman^{1,2}

¹Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

²Edinburgh Imaging, University of Edinburgh, Edinburgh, UK

³Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK

V1 First published: 16 Mar 2022, 7:94
<https://doi.org/10.12688/wellcomeopenres.17731.1>
 Latest published: 16 Mar 2022, 7:94
<https://doi.org/10.12688/wellcomeopenres.17731.1>

Abstract

Introduction: Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative disease. MS prevalence varies geographically and is notably high in Scotland. Disease trajectory varies significantly between individuals and the causes for this are largely unclear. Biomarkers predictive of disease course are urgently needed to allow improved stratification for current disease modifying therapies and future targeted treatments aimed at neuroprotection and remyelination. Magnetic resonance imaging (MRI) can detect disease activity and underlying damage non-invasively *in vivo* at the micro and macrostructural level. FutureMS is a prospective Scottish longitudinal multi-centre cohort study, which focuses on deeply phenotyping patients with recently diagnosed relapsing-remitting MS (RRMS). Neuroimaging is a central component of the study and provides two main primary endpoints for disease activity and neurodegeneration. This paper provides an overview of MRI data acquisition, management and processing in FutureMS. FutureMS is registered with the Integrated Research Application System (IRAS, UK) under reference number 169955.

Open Peer Review

Approval Status

	1	2
version 1 16 Mar 2022	 view	 view

1. **Olga Ciccarelli** , University College London, London, UK
2. **Renske Gahrman** , Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands

Any reports and responses or comments on the article can be found at the end of the article.

Methods and analysis: MRI is performed at baseline (N=431) and 1-year follow-up, in Dundee, Glasgow and Edinburgh (3T Siemens) and in Aberdeen (3T Philips), and managed and processed in Edinburgh. The core structural MRI protocol comprises T1-weighted, T2-weighted, FLAIR and proton density images. Primary imaging outcome measures are new/enlarging white matter lesions (WML) and reduction in brain volume over one year. Secondary imaging outcome measures comprise WML volume as an additional quantitative structural MRI measure, rim lesions on susceptibility-weighted imaging, and microstructural MRI measures, including diffusion tensor imaging and neurite orientation dispersion and density imaging metrics, relaxometry, magnetisation transfer (MT) ratio, MT saturation and derived g-ratio measures.

Conclusions: FutureMS aims to reduce uncertainty around disease course and allow for targeted treatment in RRMS by exploring the role of conventional and advanced MRI measures as biomarkers of disease severity and progression in a large population of RRMS patients in Scotland.

Keywords

Multiple sclerosis, magnetic resonance imaging, diffusion tensor imaging, magnetisation transfer imaging, g-ratio, susceptibility weighted imaging, protocol

Corresponding authors: Rozanna Meijboom (rozanna.meijboom@ed.ac.uk), Adam D. Waldman (adam.waldman@ed.ac.uk)

Author roles: **Meijboom R:** Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Wiseman SJ:** Data Curation, Methodology, Writing – Original Draft Preparation; **York EN:** Data Curation, Formal Analysis, Investigation, Methodology, Software, Writing – Original Draft Preparation, Writing – Review & Editing; **Bastin ME:** Formal Analysis, Methodology, Software, Writing – Review & Editing; **Valdés Hernández MdC:** Software, Writing – Review & Editing; **Thrippleton MJ:** Methodology, Writing – Review & Editing; **Mollison D:** Formal Analysis, Writing – Review & Editing; **White N:** Formal Analysis, Writing – Review & Editing; **Kampaite A:** Formal Analysis, Writing – Review & Editing; **Ng Kee Kwong K:** Formal Analysis, Visualization, Writing – Review & Editing; **Rodriguez Gonzalez D:** Resources, Writing – Review & Editing; **Job D:** Resources, Writing – Review & Editing; **Weaver C:** Project Administration, Resources, Writing – Review & Editing; **Kearns PKA:** Resources, Writing – Review & Editing; **Connick P:** Conceptualization, Funding Acquisition, Resources, Writing – Review & Editing; **Chandran S:** Conceptualization, Funding Acquisition, Resources, Supervision, Writing – Review & Editing; **Waldman AD:** Conceptualization, Funding Acquisition, Methodology, Project Administration, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: FutureMS was hosted by Precision Medicine Scotland Innovation Centre (PMS-IC) and funded by a grant from the Scottish Funding Council to PMS-IC and Biogen Idec Ltd Insurance (R44346). Additional funding for authors came from the MS Society Edinburgh Centre for MS Research (grant reference 133; RM), NHS Lothian Research and Development Office (MJT), Chief Scientist Office – SPRINT MND/MS program (ENY), the Row Fogo Charitable Trust (BROD.FID3668413; MVH) and Wellcome (223058; PKAK). Additional funding for the Edinburgh university 3T MRI Research scanner in RIE is funded by Wellcome (104916), Dunhill Trust (R380R/1114), Edinburgh and Lothians Health Foundation (2012/17), Muir Maxwell Research Fund, Edinburgh Imaging, and University of Edinburgh. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2022 Meijboom R *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Meijboom R, Wiseman SJ, York EN *et al.* **Rationale and design of the brain magnetic resonance imaging protocol for FutureMS: a longitudinal multi-centre study of newly diagnosed patients with relapsing-remitting multiple sclerosis in Scotland [version 1; peer review: 2 approved]** Wellcome Open Research 2022, 7:94 <https://doi.org/10.12688/wellcomeopenres.17731.1>

First published: 16 Mar 2022, 7:94 <https://doi.org/10.12688/wellcomeopenres.17731.1>

1. Introduction

Multiple sclerosis

Multiple sclerosis (MS) is a chronic debilitating disease of the central nervous system (CNS), for which a cure is not yet available. Pathology occurs in both white (WM) and grey matter (GM) in the brain and spinal cord and is characterised by inflammation-induced demyelination and neurodegeneration^{1,2}. Worldwide there are over two million cases of MS³. Scotland has a notably high prevalence of the disease with 290 cases per 100,000 population⁴⁻⁶. People with MS experience a wide range of symptoms, including mobility and vision problems, cognitive impairment and fatigue⁷; the severity of which varies markedly between individuals. In 85-90% of cases, MS starts with a relapsing and remitting disease course (RRMS), which in later stages generally becomes progressive (secondary progressive MS; SPMS), and the remainder have a progressive course from onset (PPMS)^{8,9}. The disease trajectory also varies significantly between individuals, the causes for which are largely unclear. Establishing early biomarkers predictive of disease course is highly important as it may allow appropriately targeted disease-modifying therapy (DMT).

FutureMS

FutureMS is a large (N=440) longitudinal multi-centre observational cohort study in Scotland aiming to develop predictive tools for disease progression and markers of disease severity in a deeply phenotyped early-stage RRMS cohort. A detailed cohort description is available in Kearns *et al.* 2021¹⁰. Brain MR imaging, focusing on both structural and microstructural techniques, is a core feature of FutureMS and is importantly being studied in the context of the whole disease with participants undergoing extensive neurological, quality of life, cognitive, retinal imaging, blood biomarker and genomic assessments at each study visit. Magnetic resonance imaging (MRI)-based biomarkers in MS are of great value, as MRI can be used to study CNS damage *in vivo* and non-invasively, offering potential as a predictor of future disability. Particularly, within the framework of a well-powered longitudinal study, changes in individual trajectory of MR measures that occur associated with treatment can be a powerful real-world marker of DMT efficacy.

Structural MRI in MS

Conventional MR imaging plays an essential role in faster MS diagnosis¹¹ as well as MS research, particularly as DMT trial end-point¹². Characteristic MS abnormalities seen on conventional MRI include periventricular, callosal, juxtacortical and infratentorial WM hyperintense lesions (WML) on T2-weighted (T2W) images; the central vein sign within WML on T2 images¹³; hypointensities ('black holes') on T1-weighted (T1W) images; and brain atrophy. Cortical brain lesions are difficult to detect on 1.5T and 3T MRI^{11,12}. WML accrual is used as indicator of interval disease activity; and T1W hypointensities and gadolinium-enhanced lesions are used as respectively indicators of irreversible damage and active inflammation^{11,12,14}. Clinical measures of disease severity/progression only show some association with brain abnormalities on conventional MRI¹⁵, which is thought to be due to limitations in both clinical disability and imaging measures^{16,17}. The number and location

(i.e. infratentorial) of WML, can be predictive of conversion from clinically isolated syndrome to MS and accumulation of disability^{18,19}. Similarly, enhancing WML and T1W 'black holes' have been associated with progression of disability²⁰⁻²². In addition, although still an area of research, there is a growing body of evidence indicating that chronic active lesions (or rim/smouldering lesions) characterised by paramagnetic rims can be identified using susceptibility weighted imaging (SWI), and are associated with increased disability²³. Spinal cord WML and atrophy are also commonly present, where damage confers a disproportionate risk of disability given the anatomical eloquence²⁴.

Processing techniques applied to conventional imaging allow for assessment of neurodegeneration through quantitative volumetric measures of whole-brain (GM and WM) atrophy. Whole-brain atrophy is present in early-stage RRMS^{18,19}, progresses over time and affects multiple brain regions²⁵. It is associated with and predictive of clinical disability^{16,18,26,27}. Although GM atrophy appears to be more closely associated with clinical progression^{28,29} and seems to decrease more extensively over time compared with WM atrophy³⁰⁻³². Overall their contribution to clinical disability remains largely unclear³³, and atrophy must be considered a downstream and non-specific indicator of neurodegeneration. Nonetheless, measures of brain volume are the most established imaging marker of neurodegeneration in MS, and have been proposed as the only measure currently sufficiently validated and reliable for use as a study endpoint³³.

Microstructural MRI in MS

Macrostructural imaging methods are widely used but provide indirect markers of the underlying pathophysiological features and leave a great deal of disease progression unaccounted for¹⁶. Quantitative MRI techniques that provide more specific markers of brain integrity on the microstructural level are becoming more established for studying demyelination and neurodegeneration in MS and may better account for clinical consequences.

Magnetisation transfer (MT) imaging provides an indirect means of detecting protons bound to semi-solid macromolecules, e.g. myelin, that are not visible on conventional sequences, via the exchange of magnetisation with the directly detectable protons of free water molecules. The most widely used MT measure is the MT ratio (MTR), which is the fractional signal reduction caused by exchange of magnetisation between these free and bound protons^{34,35}. The MTR is affected by demyelination and axonal integrity^{34,36,37} and thus reflects microstructural WM abnormalities. Previous studies have shown associations between MTR and clinical disability in MS^{12,38-41}, indicating it may have potential as a biomarker. MTR signal is, however, also affected by biophysical parameters (notably T1 relaxation time and B1 inhomogeneities), compromising its specificity to tissue microstructure⁴². MT saturation (MTsat) imaging corrects for these parameters, and provides increased contrast between WM and GM, and may therefore provide a better biomarker of microstructural WM changes than MTR^{42,43}. It has not been widely applied to MS, but associations with cognition and disability have been reported^{42,44}.

Quantitative multi-shell diffusion MRI (dMRI) provides additional markers of brain microstructure based on tissue water diffusion characteristics. Diffusion tensor imaging (DTI) models anisotropic water molecule displacement due to spatially ordered brain microarchitecture, which is particularly prominent within WM. A change in the WM microstructure will lead to a change of water molecule displacement⁴⁵. DTI parameters, comprising fractional anisotropy (FA), mean diffusivity (MD), axial (λ_{AX}) and radial (λ_{RD}) diffusivity, are sensitive to changes in the microstructure that are relevant to MS pathology⁴⁵. λ_{RD} is thought to be sensitive to demyelination⁴⁶ whereas axonal loss is mostly reflected in changes in λ_{AX} ⁴⁷. These metrics can be measured globally or regionally in tissue, but can also be combined with tractography methods⁴⁸ to assess WM tract-specific microstructural damage. In addition, multi-shell dMRI allows for neurite orientation dispersion and density imaging (NODDI) analysis, which enables more precise characterisation of WM microstructure, i.e. neurite (axon and dendrite) density, and dispersion of neurite orientation⁴⁹. Previous pathological and MRI studies have shown that neurite density is affected in MS^{50,51}.

Combining MTI and dMRI allows calculation of an MRI-derived aggregate g-ratio. The g-ratio is the ratio between the inner (i.e. axon) and outer (i.e. axon and myelin) diameter of the WM fibre and reflects myelin thickness relative to the axon radius⁵²⁻⁵⁴. Preliminary studies in small subject groups have observed g-ratio abnormalities in MS, suggestive of a thinner myelin sheath, in accordance with known pathological changes in this disease^{53,55,56}.

Relaxometry maps based on transverse (T2) or longitudinal (T1) relaxation times are also used to study underlying tissue changes. Studies suggest that quantification of T1 and combined T1 and T2 measures can be correlated with myelin content in tissue⁵⁷, and that quantitative T2 mapping of WML yields additional information related to clinical disability⁵⁸.

MRI in FutureMS

FutureMS incorporates a comprehensive MRI protocol, including visual and quantitative assessment of WML, GM and WM volumes, dMRI and MTI metrics, as well as g-ratio and relaxometry measures. These structural (conventional) imaging and quantitative microstructural metrics will be explored longitudinally with physical, cognitive and other quality of life features, blood biomarkers, genetics and retinal imaging, allowing for studying and developing predictive tools of disease progression and markers of disease severity in RRMS.

Study aim

The aim of this paper is to provide a rationale and transparent overview of MRI acquisition and processing in FutureMS, including detailed descriptions of the MRI protocol, MRI data management and MRI processing pipelines.

2. Methods

2.1 Participants

FutureMS¹⁰ recruited patients with a recent diagnosis of RRMS (<6 months)¹¹ from five neurology hubs in Scotland: Edinburgh,

Glasgow, Dundee, Aberdeen and Inverness. Further inclusion criteria were aged 18 years or older and the capacity to provide informed consent. Exclusion criteria were intake of DMTs prescribed prior to baseline assessment, participation in a clinical trial prior to baseline assessment and contraindications for MRI. Each participant received an MRI examination at baseline and 1-year follow-up, as well as a full neurological assessment, cognitive testing, and blood marker and genetic testing. Recruitment for FutureMS completed in March 2019, with a total of 440 participants (N=431 for MRI) included for baseline assessment. Sample size was determined based on simulation models of required sample size for generation of clinically useful predictive tools⁵⁹. Nine participants did not undergo MRI mainly due to fulfilling MRI exclusion criteria. One-year follow-up was completed with 392 (N=386 for MRI) participants having returned for a follow-up visit. See [Table 1](#) for demographics. Further follow-up visits will take place at 5-years and 10-years after baseline.

All patients were given a patient information sheet, had the study explained to them and gave written informed consent before study entry. The study received ethical approval on 27-01-2016 from the South East Scotland Research Ethics Committee 02 under reference 15/SS/0233 and is being conducted in accordance with the Declaration of Helsinki and ICH guidelines on good clinical practice. All imaging data and additional clinical data were anonymised with unique study identifiers.

2.2 MRI acquisition protocol

All FutureMS participants received an MRI examination consisting of structural (conventional) MRI sequences. Additionally, a selection of participants underwent sub-study protocols including SWI (N=0 at baseline, N=44 at 1-year follow-up), and the microstructural imaging techniques multi-shell dMRI and MTI (for both: N=78 at baseline and N=67 at 1-year follow-up).

2.2.1 Core study sequences: structural MRI. Structural MRI was acquired at four sites ([Table 2](#), [Table 3](#)). The Glasgow and Dundee study sites used a Siemens Prisma 3T system and Aberdeen used a Philips Achieva 3T system. Edinburgh employed two different systems for the study. Participants included in the study from the start in May 2016 up to and including October 2017 were imaged on a Siemens Verio 3T system (upgraded to Skyra Fit in July 2018; Site 1) and received their follow-up MRI on the same system. Participants included in the study as of November 2017 until the end of recruitment in March 2019

Table 1. Baseline demographics for MRI study participants.

	N	Gender (F/M)	Mean age in years (SD)	Mean EDSS (SD)
RRMS	431	321/110	38 (10.3)	2.5 (1.3)

MRI=magnetic resonance imaging, F=female, M=male, SD=standard deviation, EDSS=expanded disability status scale, RRMS=relapsing-remitting multiple sclerosis

Table 2. Equipment manufacturers across the sites participating in Future MS.

Site	Edinburgh (Site 1)	Edinburgh (Site 2)	Glasgow	Dundee	Aberdeen
Manufacturer	Siemens	Siemens	Siemens	Siemens	Phillips
Model	Verio/Skyra	Prisma	Prisma	Prisma	Achieva
Head coil	12 ch	32 ch	20 ch	20 ch	32 ch
Participants scanned at baseline	98	88	161	46	36
Started scanning	May 2016	November 2017	November 2016	December 2016	March 2017

were imaged on a Siemens Prisma 3T system (Site 2) and received their follow-up MRI on this system. Inverness study site participants were imaged at one of the other four sites.

In November 2017, the conventional MRI protocol was updated to increase between-site comparability and to facilitate improved image analysis. All participants who had been imaged before the update underwent protocol A (Table 3A), including their follow-up MRI. All patients scanned after the update were imaged with protocol B (Table 3B) at all visits. Protocol A (Table 3A) included an axial T2W, volumetric 3D T1W and two fluid attenuated inversion recovery- (FLAIR) weighted sequences: a 2D version with 3mm thick slices and no slice gap and a 3D version with 1 x 1 x 1 mm isotropic resolution. In accordance with the STRIVE guidelines⁶⁰, FLAIR was used to visualise WML. By definition, the imaging parameters of the FLAIR sequence were selected to suppress fluid signals (specifically cerebrospinal fluid (CSF)) allowing other (pathological) fluids and tissues to become conspicuous. Protocol B (Table 3B) included 3D T1W, dual echo and 2D and 3D FLAIR sequences. A dual echo sequence provided T2W and proton density (PD) images, which allowed for T2 mapping for inflammation assessment⁶¹ and for more accurate extraction of the intracranial volume (ICV). Additionally, for protocol B, parameters of all sequences were matched as closely as possible across sites to obtain maximum comparability. An overview of structural images is provided in Figure 1.

2.2.2 Sub-study sequences: SWI, dMRI and MTI. The sub-study sequences were imaged at a selection of study sites. The SWI sequence (Table 4) was acquired in Edinburgh (Site 2), Glasgow and Dundee, and implemented to investigate chronic inflammation in WML, as reflected by rim lesions. The sequence was set up as described in Sati *et al.* (2017)⁶². The SWI sub-study was added at 1-year follow-up visits only. Multi-shell dMRI⁶³ and MTI (Table 4; Figure 1) were acquired in Edinburgh (Site 2) and implemented to study myelin damage at a microstructural level. Optimised water diffusion-encoding magnetic field gradient vectors were generated as described in Caruyer *et al.* (2013)⁶³. The sub-study sequences were combined with protocol B into a single examination.

2.3 Data storage

All data were anonymised before they were transferred to the imaging research team. The recommendations of the

Brain Imaging Data Structure (BIDS; v1.0.1)⁶⁴ were followed for data storage.

2.4 Quality control

All raw imaging data were visually inspected for gross errors (e.g. ghosting and movement artefacts)⁶⁵ and data that were identified as inadequate were excluded from further processing.

2.5 Imaging outcomes

2.5.1 Qualitative assessment: WML progression. WML progression was established as a binary outcome of the presence of new/enlarging lesions at 1-year follow-up, based primarily on the FLAIR volume sequence.

2.5.2 Qualitative assessment: rim lesions on SWI. Presence of rim lesions was established for participants with SWI images acquired at 1-year follow-up. Rim lesions (Figure 2) were defined as hyperintense lesions on FLAIR which also have a hyperintense core surrounded by a hypointense rim on SWI.

2.5.3 Quantitative assessment: macrostructural outcomes. Tissue volumes for total brain, regional and global cerebral and global cerebellar normal-appearing WM (NAWM), regional and global cerebral and global cerebellar cortical GM, subcortical GM (amygdala, thalamus, hippocampus, ventral diencephalon and basal ganglia), brainstem and WML were calculated in native space for baseline and follow-up (Table 5). Tissue volume change over one year was derived for each tissue type separately by subtracting baseline from follow-up volumes.

2.5.4 Quantitative assessment: microstructural outcomes. For dMRI, the mean for FA, MD, λ_{AX} and λ_{RD} , and intracellular volume fraction (ICVF), isotropic volume fraction (ISOVF) and orientation dispersion index (ODI) was determined for the white matter skeleton (PSMD, PSAD, PSRD PSFA, PSICVF, PSISOVF and PSODI; see below). Additionally, weighted means for these measures were determined within sixteen tracts of interest identified using quantitative tractography; and their mean, median, interquartile range (IQR) and standard deviation (SD) were determined within the above brain tissue compartments (total brain, WML, cerebral and cerebellar cortical NAWM, cerebral and cerebellar cortical GM and subcortical GM) at baseline and follow-up (Table 5). Similarly, mean, median, IQR, SD and coefficient of variation (CV) for MTR, MTsat, g-ratio, quantitative T1 and T2 were established within the same

Table 3. Future MS conventional MRI parameters for protocol A and B.

A. PROTOCOL A																
Sequence	T1-weighted				T2-weighted				2D FLAIR				3D FLAIR			
	EDI1	GLA	DUN	ABN	EDI1	GLA	DUN	ABN	EDI1	GLA	DUN	ABN	EDI1	GLA	DUN	ABN
Mode	3D	3D	3D	3D	2D	2D	2D	3D	2D	2D	2D	2D	3D	3D	3D	3D
FOV (mm)	256	256	256	240	220	220	220	256	250	250	250	250	256	256 x 248	256 x 248	256
Orientation	Sag	Sag	Sag	Sag	Ax	Ax	Ax	Sag	Ax	Ax	Ax	Ax	Sag	Sag	Sag	Sag
TR (ms)	2530	2500	2500	3000	6000	6160	6160	2500	9500	9500	9500	11000	5000	5000	5000	8000
TE (ms)	3.37	2.26	2.26	3.9	96	96	96	310	124	124	124	125	715	393	393	347
TI (ms)	1100	1100	1100	1048	-	-	-	-	2400	2400	2400	2800	1800	1800	1800	2400
Flip angle (deg)	7	7	7	8	150	150	150	-	150	150	150	120	-	-	-	-
Gap (mm)	-	-	-	-	1.2	1.2	1.2	-	0	0	0	1	-	-	-	-
Matrix (mm)	256 x 256	256 x 256	256 x 256	240 x 240	320 x 320	320 x 314	314 x 314	256 x 256	256 x 256	256 x 256	256 x 256	252 x 226	256 x 256	256 x 248	256 x 248	256 x 256
Voxel size (mm)	1 x 1 x 1	1 x 1 x 1	1 x 1 x 1	1 x 1 x 1	0.7 x 0.7 x 4	0.7 x 0.7 x 4	0.7 x 0.7 x 4	1 x 1 x 1	1 x 1 x 3	1 x 1 x 3	1 x 1 x 3	1 x 1.1 x 3	1 x 1 x 1	1 x 1 x 1.3	1 x 1 x 1.3	1 x 1 x 2
Slices reconstructed	176	176	176	160	33	33	33	176	60	60	60	29	176	176	176	176
Acq. Time (m:ss)	6:03	5:59	5:59	5:38	1:26	1:03	1:03	3:42	7:38	7:38	7:38	5:08	7:22	5:32	5:32	8:32
B. PROTOCOL B																
Sequence	T1-weighted (MPRAGE)				T2-weighted dual echo (FSE)				2D FLAIR (PROPELLER)				3D FLAIR (SPACE)			
Mode	3D				2D				2D				3D			
FOV (mm)	256				250				250				256			
Orientation	Sagittal				Axial				Axial				Sagittal			
TR (ms)	2500				3630				9500				5000			
TE (ms)	2.26				9.6, 96				120				393			
TI (ms)	1100				-				2400				1800			
Flip angle (deg)	7				150				150				-			
Gap (mm)	-				0				0				-			
Matrix (mm)	256 x 256				384 x 384				256 x 256				256 x 256			
Voxel size (mm)	1 x 1 x 1				0.7 x 0.7 x 3				1 x 1 x 3				1 x 1 x 1			
Slices	176				60				60				176			
Acceleration factor (in-plane x slice)	2 x 1				3 x 1				2 x 1				2 x 1			
Acq. Time (m:ss)	5:59				4:01				4:47				6:52			

MRI=magnetic resonance imaging, FLAIR = fluid attenuated inversion recovery; EDI1 = Edinburgh site 1; GLA = Glasgow; DUN = Dundee; ABN = Aberdeen; FOV = field of view; TR = repetition time; TE = echo time; TI = inversion time; deg = degree; acq. = acquisition; Sag = sagittal; Ax = axial




Figure 1. Examples of FutureMS MR images for structural MRI and microstructural MRI (diffusion MRI, MTI and g-ratio). diffusion MRI, MT and G-ratio images are colour-coded according to the colour spectrum shown above the respective images. In the WM tract image, red is for right-left, blue for dorsal-ventral, and green for anterior-posterior tracts. Abbreviations: T1W=T1-weighted, T2W=T2-weighted, PD=proton density, FA=fractional anisotropy, MD=mean diffusivity, ODI=orientation dispersion index, ICVF=intracellular volume fraction, WM=white matter, MTI=magnetisation transfer imaging, MTR=magnetisation transfer ratio, MTSat=magnetisation transfer saturation, MRI=magnetic resonance imaging.

Table 4. FutureMS MRI sub-study parameters.

Sequence	MT on/MT off/T1W Multi-echo spoiled gradient echo	dMRI	SWI
Mode	3D	2D	3D
FOV (mm)	224 (SI) x 241 (AP)	256	250 x 218.75
Directions	-	151	-
b-value (no. of directions) (s/mm ²)	-	0 ^{rev} (3), 0 (14), 200 (3), 500 (6), 1000 (64), 2000 (64)	-
Orientation	Sagittal	Axial	Sagittal
TR (ms)	30/30/15	4300	64
TE (ms)	1.54, 4.55, 8.49	74	35
Flip angle (deg)	5/5/18	-	10
Gap (mm)	0	0	0
Matrix (mm)	160 x 172	128 x 128	384 x 336
Voxel size (mm)	1.4 x 1.4 x 1.4	2 x 2 x 2	0.65 x 0.65 x 0.65
Slices	128	74	288
Acceleration factor (in-plane x slice)	2 x 1	2 x 2	-
Acq. Time (m:ss)	6:14/6:14/3:08	11:12	7:08

MRI = magnetic resonance imaging; FOV = field of view; TR = repetition time; TE = echo time; deg = degree; acq. = acquisition; rev = reverse phase-encode direction; MT = magnetization transfer; T1W = T1-weighted; dMRI = diffusion MRI; SWI = susceptibility weighted imaging




Figure 2. A paramagnetic hypointense rim lesion in relapsing-remitting multiple sclerosis identifying chronic inflammation, as visible on susceptibility weighted imaging.

WM tracts and brain tissue compartments (only NAWM and WML for the g-ratio) at baseline and follow-up (Table 5).

2.6 Image processing

All DICOM images were converted to NIfTI-1 using `dcm2niix` v1.0, except for dMRI data, which were converted using the `TractoR` v3.3.0 package (RRID:SCR_002602)⁶⁶.

2.6.1 Qualitative assessment: WML progression. Visual rating outcomes of WML progression were determined by a neuro-radiologist (DM). All standard structural sequences for baseline and follow up imaging were reviewed using the `Carestream` v12.2.6.3000020 image viewing software, with a binary outcome of the presence of new/enlarging lesions at follow up based primarily on the FLAIR volume sequence. A random sample of 10% of studies were reviewed to assess intra- and inter-rater reproducibility, by the same observer following a delay of at least four weeks, and separately by a second neuroradiologist (ADW).

2.6.2 Qualitative assessment: rim lesions on SWI. Visual rating of rim lesions was performed on SWI. Follow-up 2D FLAIR images were registered to SWI with a rigid body registration (degrees of freedom (DOF) = 6) using FSL FLIRT (FSL v6.0.1, RRID:SCR_002823)^{67,68}. WML were identified on registered 2D FLAIR and assessed in all three anatomical

Table 5. Overview of imaging variables and regions of interest.

MRI metrics				Regions of interest	
Structural MRI	Microstructural MRI			Structural MRI	Microstructural MRI
	dMRI	MTR, MTsat, quantitative T1 & T2	G-ratio	Tissue masks ^a	WM tracts ^b
Qualitative Visual WML ratings	DTI Mean ^a , weighted mean ^b , median ^a , SD ^a , IQR ^a for: (i) Mean diffusivity	Median ^{ab}	Median ^{a*b}	Whole-brain	Corpus callosum genu
Visual rim lesion ratings	(MD) ^{ab} (ii) Fractional anisotropy (FA) ^{ab} (iii) Radial diffusivity (RD) ^{ab} (iv) Axial diffusivity (AD) ^{ab}	Mean ^{ab} IQR ^{ab} SD ^{ab} CV ^{ab}	Mean ^{a*b} IQR ^{a*b} SD ^{a*b} CV ^{a*b}	Cerebral NAWM (regional & global) Cerebellar NAWM Cerebral cortical GM (regional and global) Cerebellar GM Amygdala Basal Ganglia Thalamus Hippocampus Ventral diencephalon Brainstem WML	Corpus callosum splenium Arcuate fasciculus Anterior thalamic radiation Dorsal cingulum Ventral cingulum Corticospinal tract Inferior longitudinal fasciculus Uncinate fasciculus
Quantitative Brain tissue volume ^a	NODDI Mean ^a , weighted mean ^b , median ^a , SD ^a , IQR ^a for: (i) Intracellular volume fraction (ICVF) ^{ab} (ii) Isotropic volume fraction (ISOVF) ^{ab} (iii) Orientation dispersion index (ODI) ^{ab}				
WML volume ^a	Peak width of skeletonized diffusion PSMD, PSAD, PSRD, PSFA, PSICVF, PSISOVF, PSODI				

MTR = magnetisation transfer ratio, MTsat = magnetisation transfer saturation, MRI = magnetic resonance imaging, dMRI = diffusion magnetic resonance imaging, DTI = diffusion tensor imaging, NODDI = neurite and orientation dispersion and density imaging, PS = peak width of skeletonized, IQR = interquartile range, SD = standard deviation, CV = coefficient of variation, NAWM = normal-appearing white matter, GM = grey matter, WML = white matter lesion

^aMetrics calculated for tissue masks; ^bMetrics calculated for WM tracts, *NAWM and WML only

planes on corresponding SWI images using [ITK-SNAP v3.8.0](#) (RRID:SCR_002010)⁶⁹. Rim lesions were defined as lesions that are hyperintense on FLAIR, and are characterised by a hyperintense core partially or completely surrounded by a hypointense rim on SWI. Possible rim lesions were identified by a trained observer (KCNKK) and reviewed by a senior neuroradiologist (ADW). SWI images were also independently assessed for rim lesions by a second neuroradiologist (DM). Final rim lesion count for each subject was determined by consensus of all three raters. WML deemed too small to be reliably assessed for the presence of a rim were excluded. WML located near a high density of veins or considerable juxtacortical signal heterogeneity cannot be reliably evaluated and were therefore not considered for inclusion.

2.6.3 Structural image processing: registration and brain extraction. At each time-point, T2W, PD and 2D FLAIR images were linearly registered to the T1W image with a rigid body transformation (6 DOF) using FSL FLIRT ([FSL v6.0.1](#), RRID:SCR_002823)^{67,68}. Brain extraction was performed on baseline scans only using FSL BET2 ([FSL v6.0.1](#),

RRID:SCR_002823)⁷⁰ with different settings for each acquisition protocol. Protocol A used T1W and T2W for brain extraction while protocol B used the PD volume. The resulting baseline ICV masks were visually checked and manually edited where required using [ITK-SNAP v3.8.0](#) (RRID:SCR_002010)⁶⁹. The baseline edited ICV mask was then registered to the follow-up image space.

2.6.4 Structural image processing: WML segmentation. WML segmentation was performed on the baseline FLAIR image using an adjusted method from Zhan *et al.* (2014)⁷¹. FLAIR hyperintense tissue voxels were identified by thresholding the raw brain image intensities to values higher than 1.69 times the standard deviation above the mean. This number was tested and optimized for the current study. A lesion distribution probabilistic template generated from a sample of 277 individuals with different degrees of WML, as per Chen *et al.* (2015)⁷², was then applied to the thresholded image for excluding any hyperintense areas unlikely to reflect pathology (e.g. those produced by CSF flow artefacts around the third ventricle, in the WM tracts running perpendicular to the

acquisition plane, near some sulci, and temporal poles). Further refinement of the resulting image was achieved by applying a Gaussian smoothing, followed by thresholding the image again to remove voxels with an intensity value z-score < 0.95 (z-scores were calculated in the raw FLAIR image) and by thresholding the then remaining voxel intensity values with threshold < 0.1 . The resulting WML mask was binarised, checked and edited where necessary using *ITK-SNAP* v3.8.0 (RRID:SCR_002010)⁶⁹. For follow-up, the edited baseline WML masks were registered to follow-up space and re-edited to include any follow-up lesion changes.

2.6.5 Structural image processing: Tissue segmentation. Tissue segmentation and brain parcellation was performed using *FreeSurfer* v6.0 (RRID:SCR_001847). For each wave separately (cross-sectional), tissue segmentation was performed on the T1W and T2W images, using the default parameters (including the Desikan-Kiliany atlas⁷³) and the edited ICV as brain mask. The edited ICV masks were converted to *FreeSurfer* space and file format using *mri_convert*. All *FreeSurfer* tissue segmentations were visually assessed using an in-house snapshot software script. For incorrect segmentations, the appropriate files were corrected using *FreeView2.0* after which *FreeSurfer* was rerun using the corrected files. Segmentations that remained incorrect after manual editing were discarded. For longitudinal analysis, *FreeSurfer*'s longitudinal processing stream⁷⁴ was applied to the cross-sectional data of all waves. The longitudinal processing stream reduces random variation to increase sensitivity for correct detection of changes over time. The above described cross-sectional data were combined to form an unbiased and subject-specific template with common information of the time points. This template was then used as a base for tissue segmentation for each time point separately (longitudinal). Visual checks and corrections of longitudinal output were performed as described above. Cross-sectional and longitudinal *FreeSurfer* tissue segmentations were converted to NIFTI format and native space using respectively *FreeSurfer*'s *mri_label2vol* and *mri_convert*. *FreeSurfer* output was corrected for WML load where appropriate, using *fslmaths* (*FSL* v6.0.1, RRID:SCR_002823), resulting in tissue masks as described in section 2.5.3. Tissue volumes, as well as WML and ICV volumes, were then extracted using *fslstats* (*FSL* v6.0.1, RRID:SCR_002823).

2.6.6 dMRI processing: DTI and NODDI. *FSL* v6.0.1 tools (RRID:SCR_002823), including *FSL* *topup* and *eddy*⁷⁵, were used to extract the brain, remove bulk motion and geometric/eddy current induced distortions by registering all subsequent volumes to the first T2W echo-planar (EP) volume⁶⁷, estimate the water diffusion tensor and calculate parametric maps of MD, λ_{AX} and λ_{RD} , and FA from its eigenvalues using *DTIFIT*⁷⁶. NODDI parameters (ICVF, ISOVF and ODI) were determined from the registered dMRI data using the NODDI Matlab toolbox (RRID:SCR_006826; *MatlabR2018b*).

2.6.7 dMRI processing: PSMD. Automatic calculation of peak width of skeletonized water diffusion parameters followed the procedure described by Baykara *et al.* (2016)⁷⁷ using their

freely-available *PSMD* script. Briefly, the dMRI data were processed using the standard Tract-based Spatial Statistics (TBSS)⁷⁸ pipeline available in *FSL* (v6.0.1, RRID:SCR_002823), with histogram analysis performed on the resulting white matter MD, λ_{AX} , λ_{RD} , FA, ICVF, ISOVF and ODI skeletons. First, all participants' FA volumes were linearly and non-linearly registered to the standard space FMRIB 1 mm FA template. Second, a WM skeleton was created from the mean of all registered FA volumes. This was achieved by searching for maximum FA values in directions perpendicular to the local tract direction in the mean FA volume. An FA threshold of 0.2 was applied to the mean FA skeleton to exclude predominantly non-WM voxels. Third, MD, λ_{AX} , λ_{RD} , ICVF, ISOVF and ODI volumes were projected onto the mean FA skeleton and further thresholded at an FA value of 0.3 to reduce CSF partial volume contamination using the skeleton mask provided by 77. Finally, *PSMD*, *PSAD*, *PSRD*, *PSFA*, *PSICVF*, *PSISOVF* and *PSODI* were calculated as the difference between the 95th and 5th percentiles of the voxel-based values within each subject's DTI and NODDI skeletons.

2.6.8 dMRI processing: Tractography. Quantitative tractography employs probabilistic neighbourhood tractography (PNT) as implemented in *TractoR* v3.3.0 (RRID:SCR_002602,⁶⁶), with the underlying connectivity data generated using *FSL*'s *BedpostX/ProbTrackX* tools run with a two-fiber model per voxel, 5000 probabilistic streamlines to reconstruct each tract with a fixed separation distance of 0.5 mm between successive points. In total, 16 tracts of interest (Table 5) representing a wide range of projection, commissural and association fibers were identified in each subject using tract shape modeling in a $7 \times 7 \times 7$ voxel neighbourhood. This allowed tract-specific mean values of DTI and NODDI biomarkers, weighted by connection probability, to be determined for each tract in every subject.

2.6.9 MTI processing. Echoes for MTsat (On/Off/T1) volumes were summed together to increase signal-to-noise ratio (SNR) and the resulting MTsat-On and MTsat-T1 volumes were linearly registered to the MTsat-Off image with a rigid body transform (6 DOF). MTsat parametric maps were derived according to Helms⁴³ (<https://doi.org/10.7488/ds/2965>) and non-brain voxels were removed from the MTsat-Off image. MTR maps were also calculated from the MTsat-On and MTsat-Off images. This was followed by registration of the 3D T1W MPRAGE and tissue segmentations to the MTsat maps. Registration was done using the concatenated and inverted transformation matrix of a) linear registration of the MTsat-Off volume to the MTsat-T1 volume (7 DOF) and b) linear registration of the MTsat-T1 volume to the 3D T1W MPRAGE (12 DOF). Registered tissue segmentations were thresholded at 0.5, binarised and eroded by a sphere kernel of 1.4mm (with the exception of WML masks). The co-registered MTsat map and tissue segmentations were imported into *MATLAB* (v2018b, RRID:SCR_001622) using *spm_vol* and *spm_read_vols* (*SPM12*, RRID:SCR_007037). MTsat and MTR values within each tissue segmentation were then derived from respectively the masked MTsat and MTR map, thresholded at a range of 0 to 1 (*MatlabR2018b*, RRID:SCR_001622).

2.6.5 G-ratio. G-ratio calculation was performed by combining MTsat and dMRI measures. The MTsat map was registered to the first dMRI volume with the FSL FLIRT epi_reg script (FSL v6.0.1), with registration to the bias-corrected 3D T1W MPRAGE as an intermediary step. The Myelin Volume Fraction (MVF) is calculated as: $MVF = MTsat * k$, where k was a constant derived by assuming a g-ratio of 0.7 in the splenium of the corpus callosum for two young, healthy control subjects, scanned twice⁷⁹. NODDI and MTsat processing steps followed the patient pipeline, without a WML mask. The splenium mask was extracted from FreeSurfer segmentation of the T1-weighted MPRAGE structural image, registered to diffusion space.

The calibration factor was calculated as:

$$k = \frac{1}{\delta_{app}} * \left(1 - \left(\frac{1}{1 + \left(\left(\frac{1}{0.7^2}\right) - 1\right)(1 - v_{iso})v_{ic}}\right)\right)$$

where δ_{app} is MTsat and v_{ic} and v_{iso} are the NODDI-derived intracellular volume fraction (i.e. neurite density index) and isotropic water diffusion. The mean k value across the splenium for each individual subject and each time-point was calculated and averaged across subjects and sessions.

The Axonal Volume Fraction (AVF) was calculated as:

$$AVF = (1 - MVF)(1 - v_{iso})(v_{ic})$$

The aggregate g-ratio parametric maps were calculated voxel-by-voxel as⁵³:

$$gRatio = \sqrt{\frac{1}{(1 + MVF / AVF)}}$$

NAWM and WML segmentations were registered to the b0 diffusion volume with the transformation matrix from the FSL FLIRT epi_reg 3D T1W MPRAGE (FSL v6.0.1, RRID:SCR_002823) registration step, thresholded at 0.5 and binarised. G-ratio values within NAWM and WML segmentations were calculated.

2.6.6. Relaxometry. Quantitative T1 maps were approximated from MT-off and MT-T1 images, using the same equations in Helms⁴³ (<https://doi.org/10.7488/ds/2965>). Processing steps followed the methodology for MTI. Quantitative T2 maps were generated using the two echo times from the dual echo sequence comprising T2W and PD, in protocol B (Table 3) using:

$$T2 = \frac{TE1 - TE2}{(\log(S_{T2w}) - \log(S_{PD}))}$$

T2 maps were then linearly registered to the T1W image with a rigid body transformation (degrees of freedom = 6) and masked with tissue segmentations to derive tissue-specific quantitative T2 values.

2.7 Funding

FutureMS was funded by a grant from the Scottish Funding Council to Precision Medicine Scotland Innovation Centre

(PMS-IC) and by Biogen Idec Ltd Insurance (R44346). The SWI sub-study was separately funded by Biogen Idec Ltd Insurance.

2.8 Study organization

FutureMS is a study hosted by PMS-IC and coordinated by the Anne Rowling Regenerative Neurology Clinic, University of Edinburgh. FutureMS participants were recruited and clinically assessed (including cognitive testing and neurological assessment) by trained medical personnel at the Anne Rowling Regenerative Neurology Clinic, University of Edinburgh; Glasgow Clinical Research Facility, Queen Elizabeth University Hospital; Aberdeen Clinical Research facility, Foresterhill Site, University of Aberdeen; Clinical Research Centre in Dundee, Ninewells Hospital; Raigmore Hospital in Inverness. MRI was performed at the Queen's Medical Research Institute (QMRI) and the Royal Infirmary Edinburgh (RIE), University of Edinburgh; Clinical Research Facility Imaging Centre in Glasgow, Queen Elizabeth University Hospital; Aberdeen Biomedical Imaging Centre, Foresterhill Site, University of Aberdeen; Clinical Research Imaging Facility in Dundee, Ninewells Hospital. For participants recruited in Inverness, the MRI was performed at the site (Glasgow, Edinburgh, Dundee, and Aberdeen) most convenient for the participant. OCT imaging was performed at the Anne Rowling Regenerative Neurology Clinic, University of Edinburgh and Glasgow Clinical Research Facility, Queen Elizabeth University Hospital. FutureMS MRI data management and processing was performed at Edinburgh Imaging, Centre for Clinical Brain Sciences, University of Edinburgh. Genetic work streams were led by the University of California, San Francisco (UCSF), United States, and consisted of RNA sequencing and genotyping work performed at Edinburgh Genomics, University of Edinburgh and RNA analysis performed at UCSF, United States. Both MRI and genetic work streams were performed in close collaboration with the Anne Rowling Regenerative Neurology Clinic, University of Edinburgh.

2.9 Access to the data

The final dataset is available to all members of the FutureMS study team. Additionally, data may be made available to researchers not part of FutureMS, upon reasonable request to the corresponding author.

2.10 Patient and public involvement

Principles of research transparency with study participants and shared research priority setting has been incorporated into the study design. Participants regularly receive written research updates and are invited to join a voluntary network (Rowling Care) where they are kept up to date with research. They are also invited to in person research update presentations, which are planned to recommence in the near future having been delayed due to coronavirus disease 2019 (COVID-19) restrictions. Additionally, a sub-group of study participants meets regularly with the FutureMS research team and has been involved in setting study priorities and design.

2.11 Dissemination of results

Study results will be made available through scientific publications and will be presented at international meetings of the scientific community. In addition, study participants will

be kept informed through research updates, as described in [section 2.10](#).

2.12 Study status

FutureMS data acquisition and processing for baseline and 1-year follow-up has been completed. As per January 2022, multiple research papers using data from these time points have been published^{80–82}, made available as preprint^{10,83,84} or are in preparation. Furthermore, data acquisition for 5-year follow-up is currently ongoing, with 10-year follow-up to start in 2026.

3. Summary

MRI allows the effects of MS on the brain to be probed non-invasively, provides potential specific biomarkers of underlying pathophysiology, and forms a core component of the overall FutureMS study. The current paper provides a detailed description of the FutureMS MRI protocol.

We have developed and implemented a comprehensive FutureMS MRI pathway that allows detailed capture of brain abnormalities in MS at both a microstructural and macrostructural level. This has involved development and testing of optimized and harmonized core protocols across MRI systems at multiple centres, resilient data transfer and QA procedures, and the largely automated data processing methods required for the high volume of imaging data generated from a large clinical cohort. Structured databases have been adapted and managed for large scale complex imaging datasets, which include both primary images and secondary processed data. Sub-studies have included additional ‘advanced’ MRI techniques; specifically, dMRI and MT targeted at reporting microstructural changes as quantitative biomarkers of demyelination and axonal degeneration characteristic in MS, and SWI as an indicator of chronic inflammation. We have applied widely-used and validated methods for processing conventional and advanced MRI data and adapted methodology from previous work for specific analyses, as required. These have allowed us to calculate conventional structural metrics such as WML volume and whole-brain and regional tissue atrophy, and generate masks corresponding to NAWM, GM and WML for calculation of microstructural measures within defined tissue types. Quantitative water diffusion and MT data allow advanced metrics such as NAWM and tract-specific myelin structure, myelin thickness and neurite density to be derived.

A possible limitation of the MRI component of FutureMS is the multicenter data acquisition and possible resulting variance

in images between sites. However, multicenter MRI acquisition was required to access the MS population across Scotland and achieve adequate sample size and statistical power. A second limitation is the dual protocol implementation. Recruitment to FutureMS had started before there was an opportunity to develop and implement harmonised and optimised imaging protocols. These harmonised protocols are, however, important for a multicenter study to minimize variance in imaging measures across sites. To this end, the imaging protocol was updated after recruitment had already started, resulting in earlier participants having slightly different MRI examinations from those subsequently entering the study. Importantly, a pragmatic approach was therefore adopted to maximise imaging data consistency in which all participants received their baseline and follow-up imaging at the same site and on the same MRI system, using the same MRI protocol. Thirdly, MRI in Future MS is limited to brain, and will therefore not capture potentially important information on the role of spinal cord damage in disease severity and progression. However, possible inclusion of spinal cord imaging in a subset of participants at future follow-up visits is currently under consideration.

In conclusion, by integrating multimodal MRI, clinical, fluid biomarker and genetic data from a large population of RRMS patients in Scotland, FutureMS aims to develop predictive tools that will reduce uncertainty around disease progression and facilitate improved MS treatments.

Data availability

No data are associated with this article.

Acknowledgements

We would like to thank Dr Pascal Sati for his help with implementing the SWI sequence in the FutureMS protocol. We would also like to thank other non-author contributors of the FutureMS consortium as follows: Chris Batchelor, Fraser Brown, Tracy Brunton, Yingdi Chen, Shuna Colville, Annette Cooper, Rachel Dakin, Liz Elliott, Peter Foley, David Hunt, Aidan Hutchison, Charlotte Jardine, Lucy Kessler, Michaela Kleynhans, Jen MacFarlane, Bev MacLennan, Sarah-Jane Martin, Mary Monaghan, Scott Semple, Adam Scotson, Amy Stenson and Rosie Woodward. With special thanks to all FutureMS participants who have made this study possible. An earlier version of this article can be found on medRxiv (doi:[10.1101/2021.03.10.21253264](https://doi.org/10.1101/2021.03.10.21253264)).

References

1. Lassmann H: **Multiple Sclerosis Pathology**. *Cold Spring Harb Perspect Med*. 2018; **8**(3): a028936. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Reich DS, Lucchinetti CF, Calabresi PA: **Multiple Sclerosis**. *N Engl J Med*. 2018; **378**(2): 169–80. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. GBD 2016 Multiple Sclerosis Collaborators, Wallin MT, Culpepper WJ, *et al.*: **Global, regional, and national burden of multiple sclerosis 1990–2016: a**

- systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2019; **18**(3): 269–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. MS Society: MS in the UK. 2018.
[Reference Source](#)
 5. Mackenzie IS, Morant SV, Bloomfield GA, *et al.*: Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. *J Neurol Neurosurg Psychiatry.* 2014; **85**(1): 76–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 6. Kearns PKA, Paton M, O'Neill M, *et al.*: Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register. *J Neurol.* 2019; **266**(10): 2376–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 7. Kister I, Bacon TE, Chamot E, *et al.*: Natural history of multiple sclerosis symptoms. *Int J MS Care.* 2013; **15**(3): 146–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 8. MS Trust: Types of MS. 2018.
[Reference Source](#)
 9. Miller DH, Leary SM: Primary-progressive multiple sclerosis. *Lancet Neurol.* 2007; **6**(10): 903–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 10. Kearns PKA, Martin SJ, Chang J, *et al.*: FutureMS Cohort Profile: A Scottish Multi-Centre Inception Cohort Study of Relapsing-Remitting Multiple Sclerosis. *medRxiv.* 2021; 2021.04.15.21253274.
[Publisher Full Text](#)
 11. Thompson AJ, Banwell BL, Barkhof F, *et al.*: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 2018; **17**(2): 162–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. Cortese R, Collorone S, Ciccarello O, *et al.*: Advances in brain imaging in multiple sclerosis. *Ther Adv Neurol Disord.* 2019; **12**: 175628641985972.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 13. Sinnecker T, Clarke MA, Meier D, *et al.*: Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. *JAMA Neurol.* 2019; **76**(12): 1446.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 14. Tommasin S, Gianni C, De Giglio L, *et al.*: Neuroimaging Techniques to Assess Inflammation in Multiple Sclerosis. *Neuroscience.* 2019; **403**: 4–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Goodin DS: Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment? *Ann Neurol.* 2006; **59**(4): 597–605.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Barkhof F: The clinico-radiological paradox in multiple sclerosis revisited. *Curr Opin Neurol.* 2002; **15**(3): 239–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Mollison D, Sellar R, Bastin M, *et al.*: The clinico-radiological paradox of cognitive function and MRI burden of white matter lesions in people with multiple sclerosis: A systematic review and meta-analysis. *PLoS One.* 2017; **12**(5): e0177727.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. Rostein D, Montalban X: Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. *Nat Rev Neurol.* 2019; **15**(5): 287–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Wattjes MP, Rovira À, Miller D, *et al.*: Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. *Nat Rev Neurol.* 2015; **11**(10): 597–606.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Elliott C, Belachew S, Wolinsky JS, *et al.*: Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. *Brain.* 2019; **142**(9): 2787–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Rocca MA, Comi G, Filippi M: The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. *Front Neurol.* 2017; **8**: 433.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Losseff NA, Miller DH, Kidd D, *et al.*: The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis—preliminary results. *Mult Scler.* 2001; **7**(1): 23–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Absinta M, Sati P, Masuzzo F, *et al.*: Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. *JAMA Neurol.* 2019; **76**(12): 1474–1483.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Puz P, Steposz A, Lasek-Bal A, *et al.*: Diagnostic methods used in searching for markers of atrophy in patients with multiple sclerosis. *Neurol Res.* 2018; **40**(2): 110–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Eshaghi A, Marinescu RV, Young AL, *et al.*: Progression of regional grey matter atrophy in multiple sclerosis. *Brain.* 2018; **141**(6): 1665–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Göçmen R: The relevance of Neuroimaging Findings to Physical Disability in Multiple Sclerosis. *Noro Psikiyatr Ars.* 2018; **55**(Suppl 1): S31–S36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Minneboo A, Jasperse B, Barkhof F, *et al.*: Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. *J Neurol Neurosurg Psychiatry.* 2008; **79**(8): 917–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Jacobsen C, Hagemeyer J, Myhr KM, *et al.*: Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. *J Neurol Neurosurg Psychiatry.* 2014; **85**(10): 1109–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Filippi M, Preziosa P, Copetti M, *et al.*: Gray matter damage predicts the accumulation of disability 13 years later in MS. *Neurology.* 2013; **81**(20): 1759–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Fisher E, Lee JC, Nakamura K, *et al.*: Gray matter atrophy in multiple sclerosis: A longitudinal study. *Ann Neurol.* 2008; **64**(3): 255–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Dalton CM, Chard DT, Davies GR, *et al.*: Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. *Brain.* 2004; **127**(Pt 5): 1101–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Valsasina P, Benedetti B, Rovaris M, *et al.*: Evidence for progressive gray matter loss in patients with relapsing-remitting MS. *Neurology.* 2005; **65**(7): 1126–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Sastre-Garriga J, Pareto D, Battaglini M, *et al.*: MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. *Nat Rev Neurol.* 2020; **16**(3): 171–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Mallik S, Samson RS, Wheeler-Kingshott CA, *et al.*: Imaging outcomes for trials of remyelination in multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 2014; **85**(12): 1396–404.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Moccia M, de Stefano N, Barkhof F: Imaging outcome measures for progressive multiple sclerosis trials. *Mult Scler.* 2017; **23**(12): 1614–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Schmierer K, Scaravilli F, Altmann DR, *et al.*: Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. *Ann Neurol.* 2004; **56**(3): 407–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. van Waesberghe JH, Kamphorst W, De Groot CJA, *et al.*: Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. *Ann Neurol.* 1999; **46**(5): 747–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Faiss JH, Dähne D, Baum K, *et al.*: Reduced magnetisation transfer ratio in cognitively impaired patients at the very early stage of multiple sclerosis: a prospective, multicenter, cross-sectional study. *BMJ Open.* 2014; **4**(4): e004409.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Zhong J, Nantes JC, Holmes SA, *et al.*: Abnormal functional connectivity and cortical integrity influence dominant hand motor disability in multiple sclerosis: a multimodal analysis. *Hum Brain Mapp.* 2016; **37**(12): 4262–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Fritz NE, Keller J, Calabresi PA, *et al.*: Quantitative measures of walking and strength provide insight into brain corticospinal tract pathology in multiple sclerosis. *NeuroImage Clin.* 2017; **14**: 490–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Hayton T, Furby J, Smith KJ, *et al.*: Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. *J Neurol.* 2012; **259**(2): 237–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Lema A, Bishop C, Malik O, *et al.*: A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis. *J Neuroimaging.* 2017; **27**(2): 221–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Helms G, Dathe H, Kallenberg K, *et al.*: Erratum to: Helms, dathe, kallenberg and dechent, high-resolution maps of magnetization transfer with inherent correction for rf inhomogeneity and T₁ relaxation obtained from 3D FLASH MRI. *Magn Reson Med.* 2010; **64**(6): 1856–1856.
[Publisher Full Text](#)
 44. Lommers E, Simon J, Reuter G, *et al.*: Multiparameter MRI quantification of microstructural tissue alterations in multiple sclerosis. *NeuroImage Clin.* 2019; **23**: 101879.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Soares JM, Marques P, Alves V, *et al.*: A hitchhiker's guide to diffusion tensor imaging. *Front Neurosci.* 2013; **7**: 31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Song SK, Sun SW, Ramsbottom MJ, *et al.*: Demyelination Revealed through MRI as Increased Radial (but Unchanged Axial) Diffusion of Water. *NeuroImage.* 2002; **17**(3): 1429–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Song SK, Sun SW, Ju WK, *et al.*: Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after

- retinal ischemia. *NeuroImage*. 2003; **20**(3): 1714–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Clayden JD, Maniega SM, Storkey AJ, et al.: **TractoR: Magnetic Resonance Imaging and Tractography with R.** *J Stat Softw*. 2011; **44**(8): 1–18.
[Publisher Full Text](#)
49. Zhang H, Schneider T, Wheeler-Kingshott CA, et al.: **NODDI: Practical *in vivo* neurite orientation dispersion and density imaging of the human brain.** *NeuroImage*. 2012; **61**(4): 1000–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Evangelou N, Esiri MM, Smith S, et al.: **Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis.** *Ann Neurol*. 2000; **47**(3): 391–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Collorone S, Cawley N, Grussu F, et al.: **Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.** *Mult Scler*. 2020; **26**(13): 1647–1657.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Campbell JSW, Leppert IR, Narayanan S, et al.: **Promise and pitfalls of g-ratio estimation with MRI.** *NeuroImage*. 2018; **182**: 80–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Stikov N, Campbell JSW, Stroh T, et al.: ***In vivo* histology of the myelin g-ratio with magnetic resonance imaging.** *NeuroImage*. 2015; **118**: 397–405.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Mohammadi S, Callaghan MF: **Towards *in vivo* g-ratio mapping using MRI: unifying myelin and diffusion imaging.** 2020.
[Reference Source](#)
55. Yu F, Fan Q, Tian Q, et al.: **Imaging G-Ratio in Multiple Sclerosis Using High-Gradient Diffusion MRI and Macromolecular Tissue Volume.** *AJNR Am J Neuroradiol*. 2019; **40**(11): 1871–1877.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Hagiwara A, Hori M, Yokoyama K, et al.: **Analysis of White Matter Damage in Patients with Multiple Sclerosis via a Novel *In Vivo* MR Method for Measuring Myelin, Axons, and G-Ratio.** *AJNR Am J Neuroradiol*. 2017; **38**(10): 1934–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Ouellette R, Mangeat G, Polyak I, et al.: **Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis.** *Ann Neurol*. 2020; **87**(5): 710–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Baranovicova E, Mlynarik V, Kantorova E, et al.: **Quantitative evaluation of cerebral white matter in patients with multiple sclerosis using multicomponent T2 mapping.** *Neur Res*. 2016; **38**(5): 389–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Dobbin KK, Simon RM: **Sample size planning for developing classifiers using high-dimensional DNA microarray data.** *Biostatistics*. 2007; **8**(1): 101–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Wardlaw JM, Smith EE, Biessels GJ, et al.: **Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.** *Lancet Neurol*. 2013; **12**(8): 822–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Albrecht DS, Granziera C, Hooker JM, et al.: ***In Vivo* Imaging of Human Neuroinflammation.** *ACS Chem Neurosci*. 2016; **7**(4): 470–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Sati P, Patil S, Inati S, et al.: **Rapid MR susceptibility imaging of the brain using segmented 3d echo-planar imaging (3d EPI) and its clinical applications.** *Magnetom FLASH*. 2017; **68**: 26–32.
[Reference Source](#)
63. Caruyer E, Lenglet C, Sapiro G, et al.: **Design of multishell sampling schemes with uniform coverage in diffusion MRI.** *Magn Reson Med*. 2013; **69**(6): 1534–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Gorgolewski KJ, Auer T, Calhoun VD, et al.: **The brain imaging data structure, a format for organizing and describing outputs of neuroimaging experiments.** *Sci Data*. 2016; **3**: 160044.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Wiseman SJ, Meijboom R, Valdés Hernández MDC, et al.: **Longitudinal multi-centre brain imaging studies: guidelines and practical tips for accurate and reproducible imaging endpoints and data sharing.** *Trials*. 2019; **20**(1): 21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Clayden JD, Jentschke S, Muñoz M, et al.: **Normative Development of White Matter Tracts: Similarities and Differences in Relation to Age, Gender, and Intelligence.** *Cereb Cortex*. 2012; **22**(8): 1738–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Jenkinson M, Smith SM: **A global optimisation method for robust affine registration of brain images.** *Med Image Anal*. 2001; **5**(2): 143–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Jenkinson M, Bannister P, Brady M, et al.: **Improved optimization for the robust and accurate linear registration and motion correction of brain images.** *NeuroImage*. 2002; **17**(2): 825–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Yushkevich PA, Piven J, Hazlett HC, et al.: **User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability.** *NeuroImage*. 2006; **31**(3): 1116–28.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Smith SM: **Fast robust automated brain extraction.** *Hum Brain Mapp*. 2002; **17**(3): 143–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Zhan T, Zhan Y, Liu Z, et al.: **Automatic method for white matter lesion segmentation based on T1-fluid-attenuated inversion recovery images.** *IET Comput Vis*. 2015; **9**(4): 447–55.
[Publisher Full Text](#)
72. Chen L, Tong T, Ho CP, et al.: **Identification of Cerebral Small Vessel Disease Using Multiple Instance Learning.** In: Navab N., Hornegger J., Wells W., Frangi A. (eds) *Medical Image Computing and Computer-Assisted Intervention – MICCAI 2015*. MICCAI 2015. Lecture Notes in Computer Science, Springer, Cham, 2015; 9349.
[Reference Source](#)
73. Desikan RS, Ségonne F, Fischl B, et al.: **An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest.** *NeuroImage*. 2006; **31**(3): 968–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Reuter M, Schmansky NJ, Rosas HD, et al.: **Within-subject template estimation for unbiased longitudinal image analysis.** *NeuroImage*. 2012; **61**(4): 1402–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Smith SM, Jenkinson M, Woolrich MW, et al.: **Advances in functional and structural MR image analysis and implementation as FSL.** *NeuroImage*. 2004; **23** Suppl 1: S208–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Basser PJ, Pierpaoli C: **Microstructural and Physiological Features of Tissues Elucidated by Quantitative-Diffusion-Tensor MRI.** *J Magn Reson B*. 1996; **111**(3): 209–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Baykara E, Gesierich B, Adam R, et al.: **A Novel Imaging Marker for Small Vessel Disease Based on Skeletonization of White Matter Tracts and Diffusion Histograms.** *Ann Neurol*. 2016; **80**(4): 581–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Smith SM, Jenkinson M, Johansen-Berg H, et al.: **Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data.** *NeuroImage*. 2006; **31**(4): 1487–505.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Mohammadi S, Carey D, Dick F, et al.: **Whole-Brain *In-vivo* Measurements of the Axonal G-Ratio in a Group of 37 Healthy Volunteers.** *Front Neurosci*. 2015; **9**: 441.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Rachmadi MF, Valdés-Hernández MDC, Li H, et al.: **Limited One-time Sampling Irregularity Map (LOTS-IM) for Automatic Unsupervised Assessment of White Matter Hyperintensities and Multiple Sclerosis Lesions in Structural Brain Magnetic Resonance Images.** *Comput Med Imaging Graph*. 2020; **79**: 101685.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Ng Kee Kwong KC, Mollison D, Meijboom R, et al.: **Rim lesions are demonstrated in early relapsing-remitting multiple sclerosis using 3 T-based susceptibility-weighted imaging in a multi-institutional setting.** *Neuroradiology*. 2022; **64**(1): 109–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. York EN, Martin SJ, Meijboom R, et al.: **MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis.** *Brain Commun*. 2021; **3**(4): fcab249.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. Meijboom R, York EN, Kampaite A, et al.: **Patterns of brain degeneration in early-stage relapsing-remitting multiple sclerosis.** *medRxiv*. 2022; 2021.11.18.21266506.
[Publisher Full Text](#)
84. Chang YT, Kearns PKA, Carson A, et al.: **Data-driven analysis shows robust links between fatigue and depression in early multiple sclerosis.** *medRxiv*. 2022; 2022.01.13.22269128.
[Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 30 January 2023

<https://doi.org/10.21956/wellcomeopenres.19621.r54070>

© 2023 Gahrmann R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Renske Gahrmann 

Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Centre
Rotterdam, Rotterdam, The Netherlands

The authors describe a comprehensive overview of all imaging protocols performed in different hospitals in the FutureMS study. The study itself and the radiological analysis seems very ambitious.

Postprocessing methods are described in extensive detail for future study reference. Background of different structural and functional imaging techniques as well as the rationale behind using these techniques for the evaluation of MS-related changes are provided. The simultaneous evaluation of so many different parameters will hopefully lead to more comprehensive relatable findings, especially compared to most smaller studies that seem to focus on a single parameter only.

Comment1:

The authors state two main primary study endpoints based on imaging findings: new/enlarging WML and brain volume reduction over 1 year. There are also secondary endpoints based on advanced MRI technique-outcomes. The description of these measures as 'outcomes' seems a bit confusing as not all patients will have changes on MRI after 1 year and the study continues for several years with clinical checks. Should the radiological results not be related to the clinical outcome instead of making the radiological results a separate outcome measure?

Comment2:

In the Introduction, under Structural MRI in MS, the authors state that cortical brain lesions are difficult to detect on 1.5T and 3T MRI. But this tends to be very sequence-dependent. On Double-Inversion Recovery sequences for instance, cortical lesions are often apparent.

Comment3:

Table1 baseline demographics seems very limited to the point where it is questionable whether a table is at all necessary.

Comment4:

The extensive study protocol only includes non-contrast sequences. Breakdown or dysfunction of the BBB is a feature of active inflammatory MS plaques. Rim lesions on SWI are postulated to represent chronic inflammatory plaques, but not acute inflammation. Could the presence of active plaques affect the structural and functional results? Is there another way to measure plaque activity using the currently chosen sequences?

Comment5:

There are 16 tracts of interest chosen for quantitative tractography. Why were these tracts and this number of tracts chosen? Are there sources stating that these tracts are most likely affected in MS?

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: I am a neuroradiologist with a PhD in MR-imaging in neuro-oncology. My MS experience is clinical.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 15 November 2022

<https://doi.org/10.21956/wellcomeopenres.19621.r49263>

© 2022 Ciccarelli O. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Olga Ciccarelli 

Faculty of Brain Sciences, University College London Queen Square Institute of Neurology,
University College London, London, UK

This report describes the MRI acquisition, processing and management of data from patients

enrolled into the FutureMS cohort. In addition to conventional sequences, advanced imaging sequences were also acquired.

I have a very few and minor comments/suggestions:

- Can the authors report other baseline characteristics? For example, disease duration? type of onset?
- What is the interval between baseline MRI and last relapse?
- Can the number of patients who underwent the sub-study sequences be given in the methods?
- Are any clinical and demographic data available on the follow-up scans?

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: Non financial: I am a collaborator with ADW and SC on another project which aims to predict treatment response in MS using AI. I feel that I have been able to review impartially

Reviewer Expertise: MS, imaging

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
